Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | CA12 | O43570 | 3/20 | 0.51 |
| ▸ | CA1 | P00915 | 3/20 | 0.51 |
| ▸ | CA2 | P00918 | 3/20 | 0.51 |
| ▸ | CA9 | Q16790 | 3/20 | 0.51 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.30 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL892401 | 0.87 | MEN1 (0.77) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL5353245 | 0.86 | MEN1 (0.75) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL799678 | 0.86 | MEN1 (0.75) | MEN1PABPC1KMT2ACA12CA1 | |
| Hydrochloric Acid SCHEMBL1335355 | 0.86 | MEN1 (0.75) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL3739 | 0.84 | MEN1 (1.00) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL3270220 | 0.84 | MEN1 (1.00) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL3784250 | 0.83 | MEN1 (0.97) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL4746638 | 0.83 | MEN1 (0.97) | MEN1PABPC1KMT2ACA12CA1 | |
| Temozolomide SCHEMBL1534013 | 0.83 | MEN1 (0.97) | MEN1PABPC1KMT2ACA12CA1 | |
| SCHEMBL891881 | 0.82 | MEN1 (0.69) | MEN1PABPC1KMT2ACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183252-A1 | SUBSTITUTED IMIDAZO[5,1-d][1,2,3,5]TETRAZINES FOR THE TREATMENT OF CANCER | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230183252-A1 | SUBSTITUTED IMIDAZO[5,1-d][1,2,3,5]TETRAZINES FOR THE TREATMENT OF CANCER | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2023-06-15 | — | — | US | disclosed |
| US-20210315886-A1 | IMIDAZOTETRAZINE COMPOUNDS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2021-10-14 | — | — | US | disclosed |
| US-20210002286-A1 | IMIDAZOTETRAZINE COMPOUNDS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2021-01-07 | — | — | US | disclosed |
| WO-2020033880-A1 | IMIDAZOTETRAZINE COMPOUNDS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2020-02-13 | — | — | WO | disclosed |
| EP-2445915-B1 | 3-SUBSTITUTED-8-SUBSTITUTED-3H IMIDAZO[5,1-D][1,2,3,5-TETRAZIN-4-ONE COMPOUNDS AND THEIR USE | PHARMINOX LTD (GB) | 2016-04-20 | — | — | EP | disclosed |
| US-9024018-B2 | 3-substituted-8-substituted-3H-imidazo[5,1-d][1,2,3,5]tetrazin-4-one compounds and their use | PHARMINOX LIMITED (GB) | 2015-05-05 | — | — | US | disclosed |
| US-8552183-B2 | Process for the covalent coupling of two molecules by means of a diels-alder reaction with inverse electron requirement | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (DE) | 2013-10-08 | — | — | US | disclosed |
| US-8552183-B2 | Process for the covalent coupling of two molecules by means of a diels-alder reaction with inverse electron requirement | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (DE) | 2013-10-08 | — | — | US | disclosed |
| EP-2445915-A1 | 3-SUBSTITUTED-8-SUBSTITUTED-3H IMIDAZO[5,1-D][1,2,3,5-TETRAZIN-4-ONE COMPOUNDS AND THEIR USE | Pharminox Limited (GB) | 2012-05-02 | — | — | EP | disclosed |
| US-20120083513-A1 | 3-Substituted-8-Substituted-3H-Imidazo[5,1-d][1,2,3,5]tetrazin-4-one Compounds and Their Use | PHARMINOX LIMITED (GB) | 2012-04-05 | — | — | US | disclosed |
| US-20110274618-A1 | DIAGNOSTIC AND/OR THERAPEUTIC AGENT, METHOD FOR THE MANUFACTURE THEREOF AND USE THEREOF | LEIBNIZ-INSTITUT FUER FESTKOERPER-UND WERKSTOFFFORSCHUNG DRESDEN E.V. (DE) | 2011-11-10 | — | — | US | disclosed |
| EP-2349349-A1 | DIAGNOSTIC AND/OR THERAPEUTIC AGENT, METHOD FOR THE MANUFACTURE THEREOF AND USE THEREOF | Leibniz-Institut für Festkörper- und Werkstoffforschung Dresden e.V. (DE) | 2011-08-03 | — | — | EP | disclosed |
| WO-2010149968-A1 | 3-SUBSTITUTED-8-SUBSTITUTED-3H IMIDAZO[5,1-D][1,2,3,5-TETRAZIN-4-ONE COMPOUNDS AND THEIR USE | PHARMINOX LIMITED (GB) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010055036-A1 | DIAGNOSTIC AND/OR THERAPEUTIC AGENT, METHOD FOR THE MANUFACTURE THEREOF AND USE THEREOF | LEIBNIZ-INSTITUT FÜR FESTKÖRPER- UND WERKSTOFFFORSCHUNG DRESDEN E.V. (DE) | 2010-05-20 | — | — | WO | disclosed |
| US-20100016545-A1 | PROCESS FOR THE COVALENT COUPLING OF TWO MOLECULES BY MEANS OF A DIELS-ALDER REACTION WITH INVERSE ELECTRON REQUIREMENT | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (DE) | 2010-01-21 | — | — | US | disclosed |
| US-20100016545-A1 | PROCESS FOR THE COVALENT COUPLING OF TWO MOLECULES BY MEANS OF A DIELS-ALDER REACTION WITH INVERSE ELECTRON REQUIREMENT | DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS (DE) | 2010-01-21 | — | — | US | disclosed |
| WO-2007144200-A1 | PROCESS FOR THE COVALENT COUPLING OF TWO MOLECULES BY MEANS OF A DIELS-ALDER REACTION WITH INVERSE ELECTRON REQUIREMENT | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts (DE) | 2007-12-21 | — | — | WO | disclosed |
| EP-0252682-A2 | Tetrazines | MAY & BAKER LIMITED (GB) | 1988-01-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183252-A1 | SUBSTITUTED IMIDAZO[5,1-d][1,2,3,5]TETRAZINES FOR THE TREATMENT OF CANCER | MCL1, IDH1, IDH2 | MEN1 186/4885PABPC1 4308/4885KMT2A 453/4885 |
| US-20120083513-A1 | 3-Substituted-8-Substituted-3H-Imidazo[5,1-d][1,2,3,5]tetrazin-4-one Compounds and Their Use | MKI67, CCNA1, CCNI | MEN1 937/4885PABPC1 3125/4885KMT2A 584/4885 |
| US-20100016545-A1 | PROCESS FOR THE COVALENT COUPLING OF TWO MOLECULES BY MEANS OF A DIELS-ALDER REACTION WITH INVERSE ELECTRON REQUIREMENT | CX3CR1, NR3C2, NR4A2 | MEN1 3630/4885PABPC1 4804/4885KMT2A 3685/4885 |
| US-20210002286-A1 | IMIDAZOTETRAZINE COMPOUNDS | MCL1, IDH1, IDH2 | MEN1 736/4885PABPC1 3990/4885KMT2A 159/4885 |
| US-20210315886-A1 | IMIDAZOTETRAZINE COMPOUNDS | MCL1, IDH1, IDH2 | MEN1 736/4885PABPC1 3990/4885KMT2A 159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.